| Title of Invention | ANTI-IGF-I RECEPTOR ANTIBODY |
|---|---|
| Abstract | Antibodies, humanized antibodies, resurfaced antibodies antibody fragments, derivatized antibodies, and conjugates of same with cytotoxic agents, which specifically bind to, and inhibit, insulin-like growth factor-I receptor, antagonize the effects of IGF-I, IGF-II and serum on the growth and survival of tumor cells, and which are substantially devoid of agonist activity. The antibodies and fragments thereof may be used, optionally in conjunction with other therapeutic agents, in the treatment of tumors that express elevated levels of IGF-I receptor, such as breast cancer, colon cancer, lung cancer, ovarian carcinoma, synovial sarcoma, prostate cancer and pancreatic cancer and the derivatized antibodies may be used in the diagnosis and imaging of tumors that express elevated levels of IGF-I receptor. |
| Full Text | N/A |
|---|
795-MUMNP-2006-ABSTRACT(26-9-2008).pdf
795-MUMNP-2006-ABSTRACT(7-7-2006).pdf
795-mumnp-2006-abstract(granted)-(30-3-2009).pdf
795-MUMNP-2006-CANCELLED PAGES(26-9-2008).pdf
795-MUMNP-2006-CANCELLED PAGES(28-11-2008).pdf
795-MUMNP-2006-CLAIMS(26-9-2008).pdf
795-MUMNP-2006-CLAIMS(7-7-2006).pdf
795-MUMNP-2006-CLAIMS(AMENDED)-(28-11-2008).pdf
795-mumnp-2006-claims(granted)-(30-3-2009).pdf
795-MUMNP-2006-CORRESPONDENCE(26-9-2008).pdf
795-MUMNP-2006-CORRESPONDENCE(27-10-2008).pdf
795-MUMNP-2006-CORRESPONDENCE(29-3-2011).pdf
795-MUMNP-2006-CORRESPONDENCE(3-11-2008).pdf
795-MUMNP-2006-CORRESPONDENCE(IPO)-(3-4-2009).pdf
795-MUMNP-2006-DESCRIPTION(COMPLETE)-(26-9-2008).pdf
795-MUMNP-2006-DESCRIPTION(COMPLETE)-(7-7-2006).pdf
795-mumnp-2006-description(granted)-(30-3-2009).pdf
795-MUMNP-2006-DRAWING(26-9-2008).pdf
795-MUMNP-2006-DRAWING(7-7-2006).pdf
795-mumnp-2006-drawing(granted)-(30-3-2009).pdf
795-MUMNP-2006-FORM 1(7-7-2006).pdf
795-mumnp-2006-form 13(29-3-2011).pdf
795-MUMNP-2006-FORM 18(7-7-2006).pdf
795-mumnp-2006-form 2(26-9-2008).pdf
795-MUMNP-2006-FORM 2(COMPLETE)-(7-7-2006).pdf
795-mumnp-2006-form 2(granted)-(30-3-2009).pdf
795-MUMNP-2006-FORM 2(TITLE PAGE)-(26-9-2008).pdf
795-MUMNP-2006-FORM 2(TITLE PAGE)-(7-7-2006).pdf
795-mumnp-2006-form 2(title page)-(granted)-(30-3-2009).pdf
795-MUMNP-2006-FORM 26(27-10-2008).pdf
795-MUMNP-2006-FORM 26(3-11-2008).pdf
795-MUMNP-2006-FORM 26(7-7-2006).pdf
795-MUMNP-2006-FORM 3(19-9-2006).pdf
795-MUMNP-2006-FORM 3(7-7-2006).pdf
795-MUMNP-2006-FORM 5(26-9-2008).pdf
795-MUMNP-2006-FORM 5(7-7-2006).pdf
795-MUMNP-2006-SPECIFICATION(AMENDED)-(26-9-2008).pdf
795-MUMNP-2006-WO INTERNATIONAL PUBLICATION REPORT(7-7-2006).pdf
| Patent Number | 233416 | ||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Indian Patent Application Number | 795/MUMNP/2006 | ||||||||||||
| PG Journal Number | 14/2009 | ||||||||||||
| Publication Date | 03-Apr-2009 | ||||||||||||
| Grant Date | 30-Mar-2009 | ||||||||||||
| Date of Filing | 07-Jul-2006 | ||||||||||||
| Name of Patentee | IMMUNOGEN, INC. | ||||||||||||
| Applicant Address | 128 Sidney Street, Cambridge, Massachusetts 02139-4239, | ||||||||||||
Inventors:
|
|||||||||||||
| PCT International Classification Number | C07K16/00,A61K39/395 | ||||||||||||
| PCT International Application Number | PCT/US2004/038230 | ||||||||||||
| PCT International Filing date | 2004-12-07 | ||||||||||||
PCT Conventions:
|
|||||||||||||